PMID- 30925204
OWN - NLM
STAT- MEDLINE
DCOM- 20200214
LR  - 20200214
IS  - 1742-7843 (Electronic)
IS  - 1742-7835 (Linking)
VI  - 125
IP  - 3
DP  - 2019 Sep
TI  - Retrograde perfusion in isolated perfused mouse lungs-Feasibility and effects on 
      cytokine levels and pulmonary oedema formation.
PG  - 279-288
LID - 10.1111/bcpt.13236 [doi]
AB  - Retrograde lung vascular perfusion can appear in high-risk surgeries. The present 
      report is the first to study long-term retrograde perfusion of isolated perfused 
      mouse lungs (IPLs) and to use the tyrosine kinase ephB4 and its ligand ephrinB2 
      as potential markers for acute lung injury. Mouse lungs were subjected to 
      anterograde or retrograde perfusion with normal-pressure ventilation (NV) or 
      high-pressure ventilation (=overventilation, OV) for 4 hours. Outcome parameters 
      were cytokine, ephrinB2 and ephB4 levels in perfusate samples and bronchoalveolar 
      lavage (BAL), and the wet-to-dry ratio. Anterograde perfusion was feasible for 
      4 hours, while lungs receiving retrograde perfusion presented considerable 
      collapse rates. Retrograde perfusion resulted in an increased wet-to-dry ratio 
      when combined with high-pressure ventilation; other physiological parameters were 
      not affected. Cytokine levels in BAL and perfusate, as well as levels of soluble 
      ephB4 in BAL were increased in OV, while soluble ephrinB2 BAL levels were 
      increased in retrograde perfusion. BAL levels of ephrinB2 and ephB4 were also 
      determined in vivo, including mice ventilated for 7 hours with normal-volume 
      ventilation (NVV) or high-volume ventilation (HVV) with increased levels of ephB4 
      in HVV BAL compared to NVV. Retrograde perfusion in IPL is limited as a routine 
      method to investigate effects due to collapse for yet unclear reasons. If 
      successful, retrograde perfusion has an influence on pulmonary oedema formation. 
      In BAL, ephrinB2 seems to be up-regulated by flow reversal, while ephB4 is a 
      marker for acute lung injury.
CI  - (c) 2019 Nordic Association for the Publication of BCPT (former Nordic 
      Pharmacological Society).
FAU - Krabbe, Julia
AU  - Krabbe J
AD  - Medical Faculty, Institute of Pharmacology and Toxicology, RWTH Aachen 
      University, Aachen, Germany.
AD  - Medical Faculty, Institute of Occupational, Social and Environmental Medicine, 
      RWTH Aachen University, Aachen, Germany.
FAU - Ruske, Nadine
AU  - Ruske N
AD  - Medical Faculty, Institute of Pharmacology and Toxicology, RWTH Aachen 
      University, Aachen, Germany.
FAU - Kanzler, Stephanie
AU  - Kanzler S
AD  - Medical Faculty, Institute of Pharmacology and Toxicology, RWTH Aachen 
      University, Aachen, Germany.
FAU - Reiss, Lucy Kathleen
AU  - Reiss LK
AD  - Medical Faculty, Institute of Pharmacology and Toxicology, RWTH Aachen 
      University, Aachen, Germany.
FAU - Ludwig, Andreas
AU  - Ludwig A
AD  - Medical Faculty, Institute of Pharmacology and Toxicology, RWTH Aachen 
      University, Aachen, Germany.
FAU - Uhlig, Stefan
AU  - Uhlig S
AD  - Medical Faculty, Institute of Pharmacology and Toxicology, RWTH Aachen 
      University, Aachen, Germany.
FAU - Martin, Christian
AU  - Martin C
AD  - Medical Faculty, Institute of Pharmacology and Toxicology, RWTH Aachen 
      University, Aachen, Germany.
LA  - eng
GR  - 114/16/RWTH Aachen University/
PT  - Journal Article
DEP - 20190421
PL  - England
TA  - Basic Clin Pharmacol Toxicol
JT  - Basic & clinical pharmacology & toxicology
JID - 101208422
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (EFNB2 protein, mouse)
RN  - 0 (Ephrin-B2)
RN  - EC 2.7.10.1 (Ephb4 protein, mouse)
RN  - EC 2.7.10.1 (Receptor, EphB4)
SB  - IM
MH  - Acute Lung Injury/*diagnosis/immunology
MH  - Animals
MH  - Biomarkers/analysis
MH  - Bronchoalveolar Lavage Fluid/chemistry/immunology
MH  - Cytokines/*analysis/immunology
MH  - Disease Models, Animal
MH  - Edema/*diagnosis/immunology
MH  - Ephrin-B2/analysis
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - In Vitro Techniques/methods
MH  - Lung/immunology/*surgery
MH  - Mice
MH  - Perfusion/*adverse effects/methods
MH  - Receptor, EphB4/analysis/immunology
MH  - Respiration, Artificial/adverse effects/methods
MH  - Time Factors
MH  - Up-Regulation
OTO - NOTNLM
OT  - ephB4
OT  - ephrinB2
OT  - isolated perfused lungs
OT  - oedema formation
OT  - retrograde perfusion
EDAT- 2019/03/30 06:00
MHDA- 2020/02/15 06:00
CRDT- 2019/03/30 06:00
PHST- 2018/10/12 00:00 [received]
PHST- 2019/03/22 00:00 [accepted]
PHST- 2019/03/30 06:00 [pubmed]
PHST- 2020/02/15 06:00 [medline]
PHST- 2019/03/30 06:00 [entrez]
AID - 10.1111/bcpt.13236 [doi]
PST - ppublish
SO  - Basic Clin Pharmacol Toxicol. 2019 Sep;125(3):279-288. doi: 10.1111/bcpt.13236. 
      Epub 2019 Apr 21.